News | December 21, 2010

Three-in-One Blood Pressure Pill Approved in Germany

December 21, 2010 – A once-daily, three-in-one combination blood pressure treatment has been approved in Germany. Sevikar HCT, from Daiichi Sankyo Europe, combines olmesartan medoxomil, amlodipine, and hydrochlorothiazide (HCT) in one pill to help control hypertension.

The pill is indicated as substitution therapy in adults whose blood pressure is adequately controlled on the combination of the three drugs, taken as a dual-component and a single-component formulation.

Evidence shows that up to two-thirds of hypertensive patients require multiple medications, and many need three or more to reach the accepted blood pressure goal of 140/90 mmHg. The fixed-dose combination therapy simplifies treatment, provides patients with a more convenient option and decreases overall pill burden. Giving drugs as a single-pill fixed dose combination significantly improves compliance, and favors blood pressure control compared with the same drugs given separately as two or more pills.

Hypertension is one of the most prevalent conditions in Europe, affecting approximately one in three adults and nearly one billion people worldwide.

For more information: www.daiichisankyo.com

Related Content

Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Overlay Init